摘要
目的采用焦磷酸测序法检测有病毒学和生化学突破的慢性乙型肝炎(CHB)患者阿德福韦酯(ADV)耐药变异情况。方法选取ADV治疗出现病毒学和生化学突破的CHB患者,采用PCR产物焦磷酸测序法检测ADV耐药相关的rtA181V/T和rtN236T变异情况。结果 48例患者焦磷酸测序法检测共确认耐药变异患者14例,变异比例为29.2%(14/48)。ADV耐药变异患者中单独rtA181T/V、rtN236T变异的比例分别为64.3%(9/14)、21.4%(3/14);rtA181T/V、rtN236T混合变异比例为14.3%(2/14)。结论宜兴地区有病毒学和生化学突破的慢性乙型肝炎(CHB)患者阿德福韦酯(ADV)耐药变异以rtA181T/V变异为主,部分为rtN236T变异和tA181T/V、rtN236T混合变异。
Objective To explore the adefovir dipivoxil（ADV） resistance in chronic hepatitis B （CHB） patients by the detection of pyrosequencing. Methods Forty eight cases who failed in ADV treatment（including patients undergoing the viral and bio-chemical breakthrough） were collected. ADV associated mutations including rtA181V/T and rtN236T were detected by pyrosequencing. Results Forty eight cases were internalized. The ADV resistance positive ratio was 29.2%（14/48）. ADV resistance cases with single rtA181T/V, rtN236T mutants was 64.3%（9/14）, 21.4%（3/14）, then the rtA181T/V, rtN236T mix-mutation was 14.3%（2/14）. Conclusions The rtA181T/V mutation was predominant in patients undergoing the viral and bio-chemical breakthrough in Yixing area.
出处
《临床医学工程》
2011年第11期1748-1749,共2页
Clinical Medicine & Engineering
